Product Name: TRKA (677-684) pY680+pY681
Product Number: PE-04AHV95
Size: 200 µg      Price:74.00
1 mg      $US148.00
5 mg      325.00
Peptide Name: TRKA (677-684) pY680+pY681

Product Use: Services as a blocking peptide for use with the TrkA-pY680+pY681 rabbit polyclonal antibody (Cat. No.: AB-PK837) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y680 and Y681 phosphorylation stimulate phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: STD-pY-pY-RVG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1293.17 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: TRKA - pY680+pY681 phosphosite-specific antibody (Cat. No.: AB-PK837)

Scientific Background: TrkA (NTRK1) is a protein-tyrosine kinase of the TK group and Trk family. It is a receptor protein-tyrosine kinase with high affinity for nerve growth factor (NGF). The TrkA protein functions in the development and maturation of both the central nervous system (CNS) and peripheral nervous system (PNS) through the regulation of neuronal proliferation, differentiation, and survival, specifically of sympathetic neurons. Upon binding to NGF, TrkA undergoes homodimerization and activating autophosphorylation. Autophosphorylation of Y496 increases phosphotransferase activity and induces interaction with FRS2 and Shc1. Autophosphorylation of Y757 increases phosphotransferase activity. Autophosphorylation of Y791 increases phosphotransferase activity and induces interaction with PLCg1. Phosphorylation of Y701 inhibits phosphotransferase activity and induces interaction with CLTC and LAMP1. These interactions mediate NGF effects on cell survival and proliferation. TrkA appears to be an oncoprotein (OP). Overactive forms of the TrkA protein are known to have oncogenic properties and promote tumourigenesis. Chromosomal translocations involving the TrkA gene have been observed in thyroid papillary carcinoma tissue samples.